Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma

Recruiting now

Conditions studied: Large B-Cell Lymphoma (LBCL)

In brief

Chimeric antigen receptor (CAR) T-cell therapy has been the standard of care for relapsed/refractory large B-cell lymphomas (R/R LBCLs) since 2018. However, high cost of commercial products limits their application in real-world clinical practice. Academic approach to manufacturing CAR-T cell products can reduce the costs and improve availability and affordability of this therapy option. The aim of the present study is assess the efficacy and safety of the use of academic CAR-T cell products in r/r LBCL patients.This prospective observational study with r/r LBCL patients treated in the NN Alexandrov National Cancer Centre of Belarus. The CAR-T cell product was manufactured using lentiviral vector encoding anti-CD19 CAR.

Key facts

Study ID

NCT07524816

Run by

N.N. Alexandrov National Cancer Centre

People needed

76

Starts

2021-06-01

Expected to finish

2029-01-01

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age ≥18 years,
• relapsed or refractory LBCL,
• confirmed CD19 expression in tumor tissue,
• prior exposure to at least one line of anti-tumor therapy

You may not qualify if…

• pregnancy,
• active hepatitis B or C infection, HIV infection,
• naïve T-lymphocyte count (CD3+CCR7+CD45RO-) ≤ 0,5%

Where it is running

• NN Alexandrov National Cancer Centre of Belarus — Lyasny, Minsk Oblast, Belarus (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.